行情回顾：上周，医药生物指数上涨1.31%，跑赢沪深300 指数1.74pp，跑赢创业板综指0.36pp，在31 个子行业中排名第9。港股恒生医疗健康指数上周收跌0.11%，跑赢恒生国企指数1.97pp。上市公司研发进度跟踪：上周，上海莱士的SR604 注射液、悦康药业的YKYY013注射液的临床申请新进承办；信立泰的SAL0140 片的IND 申请新进承办。恒瑞医药的HRS-8080、诺诚健华的...
Source Link行情回顾：上周，医药生物指数上涨1.31%，跑赢沪深300 指数1.74pp，跑赢创业板综指0.36pp，在31 个子行业中排名第9。港股恒生医疗健康指数上周收跌0.11%，跑赢恒生国企指数1.97pp。上市公司研发进度跟踪：上周，上海莱士的SR604 注射液、悦康药业的YKYY013注射液的临床申请新进承办；信立泰的SAL0140 片的IND 申请新进承办。恒瑞医药的HRS-8080、诺诚健华的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.